home.social

#bioworld — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #bioworld, aggregated by home.social.

fetched live
  1. Why many global drugs never reach Japan

    For years, Japan’s “drug lag” was shorthand for slow regulatory reviews and delayed approvals compared with the U.S. and Europe. But even as regulatory timelines have shortened, review capacity has expanded and international alignment has improved, Japanese patients still face gaps in a…
    #Japan #JP #JapanNews #Asia--Pacific #BioWorld #drugdevelopment #druglag #news #PMDA #regulatory
    alojapan.com/1447760/why-many-

  2. Why many global drugs never reach Japan

    For years, Japan’s “drug lag” was shorthand for slow regulatory reviews and delayed approvals compared with the U.S. and Europe. But even as regulatory timelines have shortened, review capacity has expanded and international alignment has improved, Japanese patients still face gaps in a…
    #Japan #JP #JapanNews #Asia--Pacific #BioWorld #drugdevelopment #druglag #news #PMDA #regulatory
    alojapan.com/1447760/why-many-

  3. alojapan.com/1447760/why-many- Why many global drugs never reach Japan #AsiaPacific #BioWorld #DrugDevelopment #DrugLag #Japan #JapanNews #news #PMDA #regulatory For years, Japan’s “drug lag” was shorthand for slow regulatory reviews and delayed approvals compared with the U.S. and Europe. But even as regulatory timelines have shortened, review capacity has expanded and international alignment has improved, Japanese patients still face gaps in access to innovative drugs. B

  4. alojapan.com/1447760/why-many- Why many global drugs never reach Japan #AsiaPacific #BioWorld #DrugDevelopment #DrugLag #Japan #JapanNews #news #PMDA #regulatory For years, Japan’s “drug lag” was shorthand for slow regulatory reviews and delayed approvals compared with the U.S. and Europe. But even as regulatory timelines have shortened, review capacity has expanded and international alignment has improved, Japanese patients still face gaps in access to innovative drugs. B

  5. Bio Japan 2025: Nobel Prizes invigorate Japan’s bio industry

    Bio Japan 2025 was abuzz with the news that Japan has once again snagged the Nobel Prize in Physiology or Medicine, with Shimon Sakaguchi winning for his discover…
    #Japan #JP #JapanNews #Asia--Pacific #BioJapan #BioWorld #Celltherapy #conferences #drugdiscovery #immune #innovation #Japanese #Japanesenews #news #NobelPrize #RegcellInc. #science
    alojapan.com/1387133/bio-japan

  6. Bio Japan 2025: Nobel Prizes invigorate Japan’s bio industry

    Bio Japan 2025 was abuzz with the news that Japan has once again snagged the Nobel Prize in Physiology or Medicine, with Shimon Sakaguchi winning for his discover…
    #Japan #JP #JapanNews #Asia--Pacific #BioJapan #BioWorld #Celltherapy #conferences #drugdiscovery #immune #innovation #Japanese #Japanesenews #news #NobelPrize #RegcellInc. #science
    alojapan.com/1387133/bio-japan

  7. Research uncovers gene variant role in disease biology

    Immune New research has filled in missing links between gene variants that have been implicated in disease through…
    #NewsBeep #News #Genetics #alternativeRNAsplicing #AU #Australia #BioWorld #BioWorldMedTech #BioWorldScience #Europe #Genome-wideassociationstudies #immune #immunediseases #Macromap #macrophages #Science
    newsbeep.com/au/103494/